Status: Recruiting
Safety and Efficacy of RRG001 Gene Therapy in Subjects With Neovascular Age-related Macular Degeneration (nAMD)
A Phase I/IIa, Dose-escalation and Dose-expansion Study to Evaluate the Safety and Efficacy of Single Subretinal Injection of RRG001 in Subjects With Neovascular Age-related Macular Degeneration
Participants needed: 48
Trial details
Phase: Phase 1, Phase 2Age: 50+Biological sex: AllType: InterventionalSponsor: Shanghai Refreshgene Technology Co., Ltd.Updated: Nov 14, 2024Locations: 1
Eligibility criteria
Subjects that are willing and able to follow study procedures. [+4]
Presence of any other eye diseases other than nAMD in study eye that would affec... [+4]